Working… Menu

Radiofrequency Ablation for the Treatment of Gastric Dysplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01523912
Recruitment Status : Completed
First Posted : February 1, 2012
Last Update Posted : February 22, 2016
Information provided by (Responsible Party):
Francisco Baldaque-Silva, Hospital Sao Joao

Brief Summary:
The finding of gastric dysplasia not associated with macroscopic lesions (DNAML) or the follow-up of dysplasia after endoscopic resection (DAER) is a challenging dilemma. In the last few years, radiofrequency ablation (RFA) has become a recognized tool in the treatment of dysplastic Barrett's esophagus, but its use in gastric dysplasia has not yet been studied. The investigators aim to study the efficacy, safety and tolerability of RFA in the treatment of dysplastic gastric mucosa.

Condition or disease Intervention/treatment Phase
Gastric Dysplasia Neoplasia Device: Radiofrequency ablation of dysplastic mucosa (HALO) Phase 4

Detailed Description:

Gastric cancer is the fourth most common cancer and the second leading cause of cancer related death worldwide. The 10-year survival of patients with this malignancy is 20% due to advanced disease at the time of diagnosis. Screening programs in countries with a high incidence of gastric neoplasia aim to detect early stage cancer, suitable for curative treatment. Well-differentiated dysplastic gastric lesions limited to the mucosa (when non-ulcerated or ulcerated and less than 3 cm) or limited to the superficial submucosa (when less than 3 cm and with no lymphatic or vascular invasion) have a negligible risk of lymph node metastasis and are suitable for endoscopic curative treatment.

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been increasingly used in this setting with promising results. However, even with these advanced techniques, en bloc and R0 resection is not possible in up to 13-15% and 16-26% of the cases, respectively. The presence of dysplasia after endoscopic resection (DAER) in the post-resection scar presents a challenging dilemma due to the technical difficulty, and associated complications, of performing subsequent EMR/ESD in fibrotic tissue. Another issue of concern is the presence of gastric dysplasia not associated with macroscopic lesions (DNAML). In such cases, a targeted endoscopic treatment is difficult and clinical management is not standardized.

Radiofrequency ablation (RFA) has been increasingly advocated for the treatment of dysplastic Barrett's esophagus (BE) and early esophageal squamous cell carcinoma (ESCC), but its use in gastric dysplasia has not yet been tested. The investigators aim to study the role of gastric RFA in the treatment of DNAML and DAER.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ablation of Gastric Dysplastic Mucosa by a Novel Endoscopic Radiofrequency Device.
Study Start Date : January 2011
Actual Primary Completion Date : January 2015
Actual Study Completion Date : May 2015

Arm Intervention/treatment
Experimental: gastric RFA
Ablation of gastric dysplastic mucosa
Device: Radiofrequency ablation of dysplastic mucosa (HALO)
Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
Other Names:
  • Halo
  • RFA

Primary Outcome Measures :
  1. The % of patients with complete histological clearance of dysplasia. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Histological clearance of intestinal metaplasia [ Time Frame: 12 months ]
  2. Adverse event incidence [ Time Frame: 60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological confirmation of gastric dysplasia.
  2. The lesion is no larger than 5 cm in diameter.
  3. Age ≥ 18 years.
  4. Subject is able to tolerate endoscopy and sedation.
  5. Subject agrees to participate, fully understands content of the informed consent, and signs the informed consent form.

Exclusion Criteria:

  1. Prior gastric irradiation or surgery.
  2. Anti-platelet or anti-thrombotic medication use that can not be stopped for 7 days before and after RFA.
  3. Gastric ulcers, fistulae, varices and malignancy.
  4. History of alcohol and/or controlled substance dependency.
  5. Pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01523912

Layout table for location information
Gastroenterology Department, Hospital de Sao Joao
Porto, Portugal
Sponsors and Collaborators
Hospital Sao Joao
Layout table for investigator information
Principal Investigator: Francisco Baldaque-Silva, MD Hospital Sao Joao

Layout table for additonal information
Responsible Party: Francisco Baldaque-Silva, Principal Investigator, Hospital Sao Joao Identifier: NCT01523912     History of Changes
Other Study ID Numbers: gastric ablation
SG.HSJ.FMUP.01.2012 ( Other Identifier: Hospital Sao Joao )
First Posted: February 1, 2012    Key Record Dates
Last Update Posted: February 22, 2016
Last Verified: February 2016
Keywords provided by Francisco Baldaque-Silva, Hospital Sao Joao:
radiofrequency ablation
gastric dysplasia
gastric neoplasia
Additional relevant MeSH terms:
Layout table for MeSH terms